Mindset Pharma Inc. announced that it has filed an international patent application covering its Family 3 novel psychedelic compounds. Mindset’s Family 3 consists of certain compounds that have demonstrated half-lives extending well beyond those exhibited by comparable classical psychedelic drugs with no significant reduction in binding affinity at the serotonin 5-HT2A receptor. This application claims the priority date of Mindset’s previously filed provisional application with the United States Patent and Trademark Office (USPTO) on December 7, 2020.